E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research 


A prospective observational open-label study to evaluate the effect of telmisartan on glycosylated hemoglobin and fasting plasma glucose levels in hypertensive patients with impaired fasting glycaemia

Veena H, Narendranath S, Vinay S Yeli.

Abstract
Background: In hypertensive patients with impaired fasting glycaemia (IFG), the incidence of Type 2 diabetes mellitus is 20%, which further worsens the situation. Currently, no approved drug is available for the treatment of IFG. Telmisartan has partial agonistic activity at the PPARγ receptor, thereby reducing insulin resistance. Hence, this study was undertaken.

Aim and Objectives: Primary objective: To evaluate the effect of telmisartan on glycosylated haemoglobin (HbA1c) and fasting plasma glucose (FPG) levels. Secondary objective: To evaluate the effect of telmisartan on Body Mass Index (BMI).

Materials and Methods: In this prospective observational study, 100 newly diagnosed cases of hypertension with IFG were included. Before the treatment with telmisartan, baseline parameters such as Glycosylated haemoglobin (HbA1c), FPG, BMI, and blood pressure (BP) were recorded. Then, follow-up was done at 4, 8, and 12 weeks. BP and FPG were repeated at 4 and 8 weeks, whereas at 12 weeks all the four parameters were repeated. All the study endpoints were analyzed using paired t-test.

Results: In this study, telmisartan reduced mean HbA1c from 5.87 ± 0.09 to 5.66 ± 0.17%, FPG levels from 111.49 ± 3.82 to 104.28 ± 4.60 mg/dl, BMI from 24.20 ± 1.84 to 23.80 ± 1.75 kg/m2 and SBP from 148.44 ± 3.64 to 133.43 ± 3.00, DBP from 91.90 ± 2.37 to 82.08 ± 2.45 mm of Hg at the end of 12 weeks of treatment (P < 0.001). There were no serious adverse effects observed during the study period.

Conclusion: In this study, telmisartan reduced HbA1c, FPG, BMI, and BP values significantly. Hence, telmisartan is safe and has a significant effect on the reduction of both BP and insulin resistance.

Key words: Telmisartan; Impaired Fasting Glycaemia; Hypertension; Body Mass Index


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Veena H
Articles by Narendranath S
Articles by Vinay S Yeli
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

H V, S N, Yeli VS. A prospective observational open-label study to evaluate the effect of telmisartan on glycosylated hemoglobin and fasting plasma glucose levels in hypertensive patients with impaired fasting glycaemia. Natl J Physiol Pharm Pharmacol. 2022; 12(1): 93-96. doi:10.5455/njppp.2022.12.12434202105122021


Web Style

H V, S N, Yeli VS. A prospective observational open-label study to evaluate the effect of telmisartan on glycosylated hemoglobin and fasting plasma glucose levels in hypertensive patients with impaired fasting glycaemia. https://www.njppp.com/?mno=34572 [Access: August 03, 2022]. doi:10.5455/njppp.2022.12.12434202105122021


AMA (American Medical Association) Style

H V, S N, Yeli VS. A prospective observational open-label study to evaluate the effect of telmisartan on glycosylated hemoglobin and fasting plasma glucose levels in hypertensive patients with impaired fasting glycaemia. Natl J Physiol Pharm Pharmacol. 2022; 12(1): 93-96. doi:10.5455/njppp.2022.12.12434202105122021



Vancouver/ICMJE Style

H V, S N, Yeli VS. A prospective observational open-label study to evaluate the effect of telmisartan on glycosylated hemoglobin and fasting plasma glucose levels in hypertensive patients with impaired fasting glycaemia. Natl J Physiol Pharm Pharmacol. (2022), [cited August 03, 2022]; 12(1): 93-96. doi:10.5455/njppp.2022.12.12434202105122021



Harvard Style

H, V., S, . N. & Yeli, . V. S. (2022) A prospective observational open-label study to evaluate the effect of telmisartan on glycosylated hemoglobin and fasting plasma glucose levels in hypertensive patients with impaired fasting glycaemia. Natl J Physiol Pharm Pharmacol, 12 (1), 93-96. doi:10.5455/njppp.2022.12.12434202105122021



Turabian Style

H, Veena, Narendranath S, and Vinay S Yeli. 2022. A prospective observational open-label study to evaluate the effect of telmisartan on glycosylated hemoglobin and fasting plasma glucose levels in hypertensive patients with impaired fasting glycaemia. National Journal of Physiology, Pharmacy and Pharmacology, 12 (1), 93-96. doi:10.5455/njppp.2022.12.12434202105122021



Chicago Style

H, Veena, Narendranath S, and Vinay S Yeli. "A prospective observational open-label study to evaluate the effect of telmisartan on glycosylated hemoglobin and fasting plasma glucose levels in hypertensive patients with impaired fasting glycaemia." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 93-96. doi:10.5455/njppp.2022.12.12434202105122021



MLA (The Modern Language Association) Style

H, Veena, Narendranath S, and Vinay S Yeli. "A prospective observational open-label study to evaluate the effect of telmisartan on glycosylated hemoglobin and fasting plasma glucose levels in hypertensive patients with impaired fasting glycaemia." National Journal of Physiology, Pharmacy and Pharmacology 12.1 (2022), 93-96. Print. doi:10.5455/njppp.2022.12.12434202105122021



APA (American Psychological Association) Style

H, V., S, . N. & Yeli, . V. S. (2022) A prospective observational open-label study to evaluate the effect of telmisartan on glycosylated hemoglobin and fasting plasma glucose levels in hypertensive patients with impaired fasting glycaemia. National Journal of Physiology, Pharmacy and Pharmacology, 12 (1), 93-96. doi:10.5455/njppp.2022.12.12434202105122021